Rabeprazole - EA Pharma
Alternative Names: Aciphex; AcipHex Sprinkle; E-3810 - Eisai; LY-307640; Pariet; Pariprazole; Pariprazole sodium; Rabecure Pack 400; Rabecure Pack 800; Rabefine; Rabeloc; Rabeprazole sodium; RabletLatest Information Update: 03 Jan 2024
At a glance
- Originator Eisai Co Ltd
- Developer EA Pharma; Eisai Co Ltd
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
- Discontinued Dyspepsia
Most Recent Events
- 03 Jan 2024 No development reported - Phase-III for Helicobacter infections (Treatment-naive) in South Korea (PO)
- 05 Oct 2021 Eisai Co Ltd completes a phase III trial in Helicobacter infections (Treatment-naïve) in South Korea
- 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma